The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Abstract
The FCGR3A gene dimorphism generates two allotypes: FcgammaRIIIa-158V and FcgammaRIIIa-158F. The genotype homozygous for FcgammaRIIIa-158V (VV) is associated with higher clinical response to rituximab, a chimeric anti-CD20 IgG1 used in the treatment of B lymphoproliferative malignancies. Our objective was to determine whether this genetic association relates to rituximab-dependent cytotoxicity mediated by FcgammaRIIIa/CD16a+ cells. The number of CD16+ circulating monocytes, T cells, and natural killer (NK) cells in 54 donors was first shown to be unrelated to FCGR3A polymorphism. We then demonstrated that FcgammaRIIIa-158V displays higher affinity for rituximab than FcgammaRIIIa-158F by comparing rituximab concentrations inhibiting the binding of 3G8 mAb (anti-CD16) with VV NK cells and NK cells homozygous for FcgammaRIIIa-158F (FF). VV and FF NK cells killed Daudi cells similarly after FcgammaRIIIa engagement by saturating concentrations of rituximab or 3G8. However, the rituximab concentration resulting in 50% lysis (EC(50)) observed with NK cells from VV donors was 4.2 times lower than that observed with NK cells from FF donors (on average 0.00096 and 0.00402 microg/ml, respectively, P = 0.0043). Finally, the functional difference between VV and FF NK cells was restricted to rituximab concentrations weakly sensitizing CD20. This study supports the conclusion that FCGR3A genotype is associated with response to rituximab because it affects the relationship between rituximab concentration and NK cell-mediated lysis of CD20+ cells. Rituximab administration could therefore be adjusted according to FCGR3A genotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CD20-targeting mAbs such as rituximab, obinutuzumab, ocaratuzumab, and ofatumumab”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Dall'Ozzo et al., 2004
In the citing paper
“a variety of mAbs targeting malignant cells mediate immunostimulation upon the engagement of ADCC, ADCP, or complement-dependent cytotoxicity”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Dall'Ozzo et al., 2004
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“The implication of both Fc R and C1q in the in vivo antitumor effect of rituximab against CD20 lymphoma cell lines has been clearly demonstrated in murine models (20, 21), suggesting that ADCC and complement activation are essential for rituximab therapeutic effect.”
BackgroundMcLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755 · cited 2×
“Therefore, variability at both the tumor cell level and the patient’s immune system level may influence the response to rituximab, in addition to the tumor burden at the time of treatment (10) and rituximab concentrations obtained in patients (8, 38).”
BackgroundDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900 · cited 2×
“We have recently shown an association between FCGR3A genotype and response to rituximab in previously untreated follicular NHL patients with low tumor burden ( 22 ).”
BackgroundSelf-citationShields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 1×
“More generally, such a pharmacogenetic approach has to be taken into account to improve therapeutic efficacy of cytolytic mAbs in addition to methods that have been shown to enhance NK cell response to tumor cells, such as engineering the Fc portion to increase mAb binding to FcRIIIa (32, 44 ) or stimulating NK cells…”
BackgroundWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“The association between FCGR3A genotype and clinical response to rituximab has also been observed in relapsed follicular NHL patients ( 23 ) and in Waldenstro ¨m’s macroglobulinemia patients (24).”
BackgroundShields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Coiffier, B., Haïoun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D. D. F., Johnson, P., Lister, A., Feuring‐Buske, M., Radford, J. A., et al. (1998) · PubMed · doi:10.1182/blood.v92.6.1927 · Cited by 893
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
Cited by
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Rituximab: Mechanism of Action
Weiner, G. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.011 · Cited by 786
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
“an effect on cellular cytotoxicity, not an effect on pharmacokinetics.([69]) A second elimination route is degradation within the target cell, which occurs after internalization and subsequent intracellular degradation in lysosomes.”
Background
Metadata
- Authors
- Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G.
- Affiliations
- 1Laboratoire d’Immunologie,
- Université de Tours (FR)
- Venue
- Cancer Research
- Published
- 2004-07-01
- Volume
- 64
- Issue
- 13
- Pages
- 4664-4669
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1914229355
- Cited by
- 434
- References
- 47
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 13 · 2023: 10 · 2022: 12 · 2021: 15 · 2020: 13 · 2019: 20 · 2018: 20 · 2017: 21 · 2016: 24 · 2015: 28 · 2014: 28 · 2013: 27 · 2012: 29
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- rituximab, natural killer cells, FCGR2A, CD16, CD20, Daudi cells, individualized dosing
- MeSH terms
- Rituximab, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Cells, Cultured, Dose-Response Relationship, Immunologic, Genotype, Humans, Killer Cells, Natural, Polymorphism, Genetic, Receptors, IgG, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab-Dependent Cytotoxicity by Natural Killer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-03-2862
- The paper
- Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004). Rituximab-Dependent Cytotoxicity by Natural Killer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-03-2862
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.